Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)‘s stock had its “hold” rating reissued by equities researchers at Cowen and Company in a research note issued to investors on Thursday, November 2nd.
The analysts wrote, “Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of.””
A number of other research analysts also recently commented on SNSS. Cantor Fitzgerald reiterated a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a report on Wednesday, September 27th. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, ValuEngine downgraded Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Sunesis Pharmaceuticals currently has an average rating of “Hold” and an average target price of $4.17.
Sunesis Pharmaceuticals (NASDAQ SNSS) traded up $0.17 on Thursday, reaching $3.04. The company had a trading volume of 282,070 shares, compared to its average volume of 121,678. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $4.45. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same period in the prior year, the firm posted ($0.62) earnings per share. equities analysts forecast that Sunesis Pharmaceuticals will post -1.57 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Cowen and Company Reiterates “Hold” Rating for Sunesis Pharmaceuticals, Inc. (SNSS)” was first posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://baseballnewssource.com/markets/sunesis-pharmaceuticals-inc-snss-receives-hold-rating-from-cowen-and-company/1751470.html.
In other Sunesis Pharmaceuticals news, major shareholder Mpm Oncology Impact Management purchased 25,300 shares of Sunesis Pharmaceuticals stock in a transaction dated Thursday, November 2nd. The stock was acquired at an average cost of $2.59 per share, with a total value of $65,527.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Dayton Misfeldt purchased 400,000 shares of Sunesis Pharmaceuticals stock in a transaction dated Friday, October 27th. The stock was acquired at an average cost of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 506,800 shares of company stock valued at $1,091,282 over the last ninety days. 10.21% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its holdings in shares of Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares during the period. Virtu KCG Holdings LLC purchased a new position in Sunesis Pharmaceuticals in the 2nd quarter valued at approximately $208,000. Renaissance Technologies LLC increased its stake in Sunesis Pharmaceuticals by 1.1% in the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. increased its stake in Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 68,212 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares in the last quarter. 39.43% of the stock is owned by institutional investors and hedge funds.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.